Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9229133 | 0.98 | TLR8 (0.49) | TLR8TLR7SLC9A1MPOMEN1 | |
| SCHEMBL29311541 | 0.98 | TLR8 (0.49) | TLR8TLR7SLC9A1MPOMEN1 | |
| SCHEMBL18073162 | 0.95 | TLR8 (0.55) | TLR8TLR7SLC9A1MPOMEN1 | |
| SCHEMBL10123647 | 0.87 | SLC6A2 (0.44) | TLR8TLR7SLC9A1MEN1CYP1A2 | |
| SCHEMBL9038635 | 0.81 | SLC9A1 (0.44) | TLR8TLR7SLC9A1MEN1KMT2A | |
| SCHEMBL17981794 | 0.81 | PDE4D (0.42) | TLR8TLR7MPOMEN1KMT2A | |
| SCHEMBL30177201 | 0.80 | IRAK4 (0.43) | TLR8TLR7MPOKMT2AALDH1A1 | |
| SCHEMBL28267672 | 0.80 | KMT2A (0.41) | TLR8TLR7MEN1CYP1A2CYP2C19 | |
| SCHEMBL5764690 | 0.80 | SLC6A2 (0.43) | TLR8TLR7SLC9A1MEN1CYP1A2 | |
| SCHEMBL8803926 | 0.79 | TLR8 (0.40) | TLR8TLR7KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183450-B | Synthetic method of 2-arylindazolo maleimide fused polycyclic compound | 河南师范大学 | 2020-05-12 | — | — | CN | claimed |
| CN-110183450-A | A kind of synthetic method of 2- arylindazoles and maleimide fused-polycyclic compounds | 河南师范大学 | 2019-08-30 | — | — | CN | claimed |
| CN-110183456-A | A kind of synthetic method of 2- arylindazoles succinimide spiro-compound | 河南师范大学 | 2019-08-30 | — | — | CN | claimed |
| WO-2016001682-A1 | TREATMENT OF HYPERTRANSAMINASEMIA | SUMMIT THERAPEUTICS PLC (GB) | 2016-01-07 | — | — | WO | claimed |
| EP-3428148-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-110183450-B | Synthetic method of 2-arylindazolo maleimide fused polycyclic compound | 河南师范大学 | 2020-05-12 | — | — | CN | disclosed |
| CN-110183450-A | A kind of synthetic method of 2- arylindazoles and maleimide fused-polycyclic compounds | 河南师范大学 | 2019-08-30 | — | — | CN | disclosed |
| CN-110183456-A | A kind of synthetic method of 2- arylindazoles succinimide spiro-compound | 河南师范大学 | 2019-08-30 | — | — | CN | disclosed |
| CN-110183456-A | A kind of synthetic method of 2- arylindazoles succinimide spiro-compound | 河南师范大学 | 2019-08-30 | — | — | CN | disclosed |
| CN-110183450-A | A kind of synthetic method of 2- arylindazoles and maleimide fused-polycyclic compounds | 河南师范大学 | 2019-08-30 | — | — | CN | disclosed |
| CN-110183450-A | A kind of synthetic method of 2- arylindazoles and maleimide fused-polycyclic compounds | 河南师范大学 | 2019-08-30 | — | — | CN | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON MANUFACTURING, LTD. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2008016993-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON RESEARCH, LTD. (US) | 2008-02-07 | — | — | WO | disclosed |
| CN-1056834-C | Novel arylindazoles and their use as herbicides | ZENECA LTD (GB) | 2000-09-27 | — | — | CN | disclosed |
| US-5928998-A | PRE- AND POSTEMERGENCE HERBICIDES | ZENECA LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5444038-A | Arylindazoles and their use as herbicides | ZENECA LIMITED (GB) | 1995-08-22 | — | — | US | disclosed |
| EP-0630367-A1 | NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993018008-A1 | NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES | ZENECA LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | TLR8 4645/4885TLR7 2587/4885SLC9A1 3280/4885 |
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | HTR3B, HTR3A, HTR4 | TLR8 1192/4885TLR7 1145/4885SLC9A1 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.